Yucel Selcuk, Akkaya Erdem, Guntekin Erol, Kukul Erdal, Akman Sema, Melikoglu Mustafa, Baykara Mehmet
Department of Urology, Akdeniz University School of Medicine, Antalya, Turkey.
J Urol. 2005 Oct;174(4 Pt 2):1612-5; discussion 1615. doi: 10.1097/01.ju.0000179241.99381.5e.
Traditional treatment of dysfunctional voiding in children with urinary retention involves retraining the pelvic floor muscles using biofeedback. Alpha-blockers are reported to also be effective in children with urinary retention and dysfunctional voiding. We compared the efficacy of biofeedback and alpha-blockers for dysfunctional voiding and urinary retention in terms of residual urine volume and urge incontinence episodes, mean flow rates and urinary tract infections.
A total of 28 patients with a mean age of 6.25 years (range 4 to 10) presented with symptoms of urinary incontinence, urgency and urinary tract infections without anatomic and neurogenic causes of urinary retention. All patients had increased post-void residual (PVR) urine volume (mean 59 ml, 32% of age expected capacity [AEC]). The biofeedback group consisted of 16 children (mean age 6.5 years) and the alpha-blocker group consisted of 12 children (mean age 5.9 years). Both groups were also on continued timed voiding, constipation treatment and anticholinergics, which had been used for at least the last 6 months. Biofeedback (median 10, range 6 to 16 sessions) and doxazosin (0.5 to 2 mg) were administered. At 3 and 6 months incontinence episodes, urinary tract infections, mean urinary flow rates, PVR and parental satisfaction grades (1 to 10) were reevaluated. Six refractory cases were started on alpha-blockers and biofeedback, and reevaluated after 1 month and 3 months.
Pretreatment mean PVR was 54 ml (30% of AEC), and mean posttreatment PVR was 21 ml (12% of AEC) and 9 ml (5% of AEC) at 3 and 6 months in the biofeedback group (p <0.05). Pretreatment mean PVR was 64 ml (38% of AEC), and posttreatment mean PVR was 17 ml (12% of AEC) and 13 ml (8% of AEC) at 3 and 6 months in the alpha-blocker group (p <0.05). There was no statistical difference in posttreatment PVR between the 2 groups (p >0.05). High PVR persisted in 4 (25%) biofeedback cases and in 2 (16%) alpha-blocker cases. Complete improvement in urge incontinence episodes occurred in 10 (62.5%) and 7 (70%) children in the biofeedback and alpha-blocker groups, respectively. In therapy responsive children parental satisfaction was higher with alpha-blocker than with biofeedback (9.2 vs 7.9, p <0.05). Refractory high PVR decreased significantly after combination treatment with biofeedback and alpha-blocker in 5 of 6 children (mean 80 ml, 35% of AEC vs mean 15 ml, 7% of AEC). No drug related side effect was reported in the alpha-blocker group.
Alpha-blocker therapy seems to be a viable alternative to biofeedback in dysfunctional voiding in children with urinary retention to improve bladder emptying. Combination treatment (biofeedback and alpha-blockers) can be used as additional therapy in refractory cases.
传统上,对于存在尿潴留的儿童功能性排尿障碍的治疗包括使用生物反馈来重新训练盆底肌肉。据报道,α受体阻滞剂对存在尿潴留和功能性排尿障碍的儿童也有效。我们从残余尿量、急迫性尿失禁发作次数、平均尿流率和尿路感染方面比较了生物反馈和α受体阻滞剂对功能性排尿障碍和尿潴留的疗效。
共有28例平均年龄6.25岁(范围4至10岁)的患者,表现为尿失禁、尿急和尿路感染症状,且不存在导致尿潴留的解剖学和神经源性原因。所有患者排尿后残余(PVR)尿量均增加(平均59 ml,为预期年龄容量[AEC]的32%)。生物反馈组由16名儿童(平均年龄6.5岁)组成,α受体阻滞剂组由12名儿童(平均年龄5.9岁)组成。两组均继续进行定时排尿、便秘治疗和使用抗胆碱能药物,这些措施至少已使用6个月。给予生物反馈(中位数10次,范围6至16次)和多沙唑嗪(0.5至2 mg)。在3个月和6个月时,重新评估尿失禁发作次数、尿路感染、平均尿流率、PVR以及家长满意度评分(1至10分)。6例难治性病例开始使用α受体阻滞剂和生物反馈治疗,并在1个月和3个月后重新评估。
生物反馈组治疗前平均PVR为54 ml(AEC的30%),治疗后3个月和6个月时平均PVR分别为21 ml(AEC的12%)和9 ml(AEC的5%)(p<0.05)。α受体阻滞剂组治疗前平均PVR为64 ml(AEC的38%),治疗后3个月和6个月时平均PVR分别为17 ml(AEC的12%)和13 ml(AEC的8%)(p<0.05)。两组治疗后PVR无统计学差异(p>0.05)。4例(25%)生物反馈治疗病例和2例(16%)α受体阻滞剂治疗病例中PVR持续较高。生物反馈组和α受体阻滞剂组分别有10例(62.5%)和7例(70%)儿童的急迫性尿失禁发作完全改善。在治疗有反应的儿童中,家长对α受体阻滞剂的满意度高于生物反馈(9.2对7.9,p<0.05)。6例儿童中有5例在联合使用生物反馈和α受体阻滞剂治疗后难治性高PVR显著降低(平均80 ml,AEC的35%对平均15 ml,AEC的7%)。α受体阻滞剂组未报告与药物相关的副作用。
对于存在尿潴留的儿童功能性排尿障碍,α受体阻滞剂治疗似乎是生物反馈的一种可行替代方法,可改善膀胱排空。联合治疗(生物反馈和α受体阻滞剂)可用于难治性病例的附加治疗。